This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA was retained on behalf of the plaintiff in a litigation regarding alleged misappropriation of confidential information and trade secrets relating to complement therapy technology by multiple defendants.
CRA calculated actual loss, reasonable royalty damages, and unjust enrichment due to the plaintiff. Dr. Gregory K Bell provided opening and reply reports and deposition testimony. Dr. Bell was supported by Ms. Erin McDermott.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comIn this article titled “Smallest saleable patent-practicing unit in life sciences disputes,” author Erin McDermott examines methods for calculating damages in...
Antitrust Economics for Lawyers, published by LexisNexis and written by CRA consultants and affiliated experts, is geared towards attorneys in antitrust...
